5.7 Drugs & Conditions Prohibiting Dispensing
Key Takeaways
- Dispensing an expired drug, a recalled product, or a misbranded/adulterated drug is prohibited under the FDCA and PA's 35 P.S. §§ 780-101 et seq.; the product becomes misbranded.
- Drugs with FDA REMS (e.g., isotretinoin under iPLEDGE, clozapine, thalidomide) may not be dispensed without fulfilling REMS elements under FDCA § 505-1.
- Under 21 CFR § 1306.04(a), a pharmacist shares corresponding responsibility with the prescriber; filling prescriptions with diversion red flags creates co-liability.
- A prescription from a DEA-disenrolled prescriber is invalid; filling it is a corresponding-responsibility violation.
- PA ethics rules restrict pharmacist self-dispensing and dispensing to immediate family members except in emergencies or where an independent prescriber issued the prescription.
When the Pharmacist Must Not Dispense
A pharmacist's first professional duty is to refuse to dispense when the law or patient safety forbids it. PA and federal law identify several categories of drugs and conditions where dispensing is prohibited or restricted. Filling in the face of these prohibitions exposes the pharmacist to Board discipline, civil penalties, and DEA registration revocation.
Statutory Prohibitions at a Glance
| Prohibition | Authority | Consequence of dispensing |
|---|---|---|
| Expired drug | 21 CFR § 201.18; USP <659> | Misbranded under FDCA § 502 |
| Recalled product | 21 USC § 360h (FDCA § 504); FDA recall classes I/II/III | Misbranded; potentially adulterated |
| Misbranded or adulterated | FDCA §§ 501, 502 | Board discipline; product seizure |
| REMS-restricted without authorization | FDCA § 505-1 | Drug is misbranded without REMS elements |
| DEA-disenrolled prescriber | 21 CFR § 1301.41 | Invalid prescription; corresponding responsibility |
| Self or family (PA ethics) | 49 Pa. Code § 27.18; PA Pharmacy Act § 390-7 | Board discipline |
| Dangerous combinations | 21 CFR § 1306.04 (corresponding responsibility) | Pharmacist shares liability |
Expired, Recalled, Misbranded, and Adulterated
An expired drug is one whose manufacturer expiration date has passed. USP <659> treats expired drugs as outside acceptable use; dispensing one misbrands the product under FDCA § 502. PA enforcement follows the same rule. A drug past its BUD set at dispensing is also un-dispensable, even if the manufacturer expiration has not been reached.
A recalled product must be quarantined pending return to the supplier or destruction. The pharmacy must document receipt of recall notices, segregate stock, and notify patients who received the affected product when patient-level action is warranted (Class I or patient-safety Class II recalls).
A misbranded drug fails label or statutory requirements (e.g., false or misleading labeling, omissions of § 27.18(d) elements). An adulterated drug is one prepared, packed, or held under insanitary conditions, or that fails strength, quality, or purity standards (FDCA § 501).
REMS Before Dispensing
A drug with an FDA-approved Risk Evaluation and Mitigation Strategy (REMS) under FDCA § 505-1 may require the pharmacy to enroll in the REMS program, obtain patient acknowledgment (e.g., the isotretinoin iPLEDGE program), verify prescriber certification, or dispense only with a Medication Guide. The pharmacist must confirm REMS elements before dispensing. Examples include isotretinoin (iPLEDGE), clozapine (monitoring ANC), mifepristone, and thalidomide/lenalidomide (Celgene REMS). Dispensing a REMS drug without fulfilling REMS elements is misbranding.
Dangerous Drug Combinations and Corresponding Responsibility
Under 21 CFR § 1306.04(a), a controlled-substance prescription is valid only if issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. The pharmacist shares corresponding responsibility with the prescriber. Filling obvious dangerous combinations — e.g., concurrent opioids plus benzodiazepines without clinical justification — or recognized "drug-seeking" red flags (multiple prescribers, early refills, cash payment for controlled substances) exposes the pharmacist to the same penalties as the prescriber. PA PDMP query requirements under Act 191 of 2014 (ABC-MAP) apply each time an opioid or benzodiazepine is prescribed (see § 5.3). A pharmacist who nonetheless dispenses after recognizing red flags is not "passing through" — they are co-liable.
Right to Refuse to Dispense
A pharmacist may refuse to dispense any prescription when, in professional judgment, the prescription is invalid, unsafe, or outside the pharmacist's scope (e.g., conflicts with clinical guidelines, suspected forgery, drug interaction, or the pharmacy lacks the drug). PA permits pharmacists to decline to dispense for conscience reasons (e.g., emergency contraception, hormonal contraception), but the pharmacy must ensure the patient can obtain the medication through another channel — Board guidance requires that a pharmacy declining to dispense for conscience reasons provide timely referral or transfer.
DEA Disenrollment
A prescriber whose DEA registration is disenrolled — revoked, surrendered, expired, or never held — may not issue valid controlled-substance prescriptions. Before dispensing CII–CV, the pharmacist should verify DEA status via the DEA lookup tool. A prescription from a disenrolled prescriber is invalid; filling it is a corresponding-responsibility violation.
Self and Family Dispensing — PA Ethics
PA follows the general rule that a pharmacist should not prescribe or dispense to themselves or to immediate family members, except in emergencies. The PA Board's Code of Conduct for pharmacists (49 Pa. Code § 27.18; PA Pharmacy Act § 390-7) treats self-dispensing as creating a conflict of interest and a risk to professional judgment. Exceptions: emergency situations where no other prescriber is reasonably available, or where the family member is a regular patient of the pharmacy and the prescription is issued by an independent prescriber with no relation to the dispensing pharmacist.
Common MPJE Traps
- Dispensing a drug past its BUD but before manufacturer expiration — still misbranded.
- Filling a prescription from a prescriber with a lapsed DEA registration — invalid prescription.
- Treating a recalled product as returnable "later" — the pharmacy must quarantine immediately upon notice.
- Self-prescribing antibiotics for a sinus infection — outside PA ethics rules even with a physician collaborator.
- Assuming conscience-based refusal ends the pharmacy's duty — referral or transfer is still required.
A drug's manufacturer expiration date has not been reached, but the pharmacist assigned a 60-day BUD at dispensing and that BUD has passed. The patient returns with the original dispensed container requesting more of the same tablets from that bottle. What must the pharmacist do?
Which scenario creates corresponding-responsibility liability for the pharmacist under 21 CFR § 1306.04(a)?
Which statement is correct regarding PA pharmacist self-dispensing under 49 Pa. Code § 27.18 and the PA Pharmacy Act?